

Supplementary Online Content

Wu L, Song H, Zhang C, et al. Efficacy and safety of Pannax notoginseng saponins in the treatment of adults with ischemic stroke in China. *JAMA Netw Open*. 2023;6(6):e2317574. doi:10.1001/jamanetworkopen.2023.17574

eTable 1. Efficacy Outcomes at 12 Months in the Modified Intention-to-Treat Cohort

eTable 2. Distribution of the Modified Rankin Scale at 3 Months in the Modified Intention-to-Treat Cohort

eTable 3. Efficacy Outcomes at 3 Months in the Per-Protocol Cohort

eTable 4. Efficacy Outcomes at 12 Months in the Per-Protocol Cohort

eTable 5. Medications and Status at 1 Month in the Modified Intention-to-Treat Cohort

eFigure 1. Distribution of the Modified Rankin Scale at 3 Months in the Per-Protocol Cohort

eFigure 2. Subgroup Analyses in the Per-Protocol Cohort

eAppendix. Trial Organization

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Efficacy Outcomes at 12 Months in the Modified Intention-To-Treat Cohort

	XST group (n=1487)	Control group (n=1479)	OR/HR (95% CI)	P value
Secondary outcomes				
Recurrent stroke, n (%)	33 (2.2)	41 (2.8)	0.80 (0.51 to 1.26)	0.34
Functional independence, n (%) ^a	1342 (92.4)	1324 (91.5)	1.13 (0.87 to 1.48)	0.36
No or minimal disability, n (%) ^a	1243 (85.6)	1191 (82.3)	1.27 (1.05 to 1.53)	0.01
Composite cerebrovascular events, n (%)	39 (2.6)	45 (3.0)	0.86 (0.56 to 1.32)	0.49
EQ-5D score, median (IQR) ^a	95 (90, 98)	94 (90, 96)	-	0.009
Barthel Index change from baseline to 12 months, median (IQR) ^a	20 (5, 40)	20 (5, 40)	-	0.17

XST, Xuesaitong soft capsule; OR, odds ratio; HR, hazard ratio; CI, confidence interval; EQ-5D, EuroQoL Group 5-Dimension; IQR, interquartile range.

^a Functional outcome data at 12 months were missing in 67 patients; Data of EQ-5D score at 12 months were missing in 84 patients; Data of Barthel Index change from baseline to 12 months were missing in 80 patients; The number of missing data was similar between the two groups.

eTable 2. Distribution of the modified Rankin Scale at 3 months in the modified Intention-To-Treat Cohort

The score of modified Rankin Scale, n (%)	XST group (n=1487)	Control group (n=1479)
0	348 (23.4)	320 (21.6)
1	754 (50.7)	705 (47.7)
2	226 (15.2)	193 (13.1)
3	89 (6.0)	192 (13.0)
4	65 (4.4)	65 (4.4)
5	4 (0.3)	2 (0.1)
6	1 (0.1)	2 (0.1)

XST, Xuesaitong soft capsule.

eTable 3. Efficacy Outcomes at 3 months in the Per-Protocol Cohort

	XST group (n=1081)	Control group (n=1096)	OR/HR (95% CI)	P value
Primary outcome				
Functional independence, n (%)	973 (90.0)	913 (83.3)	1.98 (1.51 to 2.60)	<0.001
Secondary outcomes				
Recurrent stroke, n (%)	9 (0.8)	9 (0.8)	1.02 (0.40 to 2.56)	0.98
No or minimal disability, n (%)	813 (75.2)	774 (70.6)	1.26 (1.04 to 1.53)	0.02
NIHSS score change from baseline to 3 months, median (IQR) ^a	-4 (-5, -3)	-4 (-5, -3)	-	0.07
Composite cerebrovascular events, n (%)	9 (0.8)	10 (0.9)	0.91 (0.37 to 2.25)	0.84
EQ-5D score, median (IQR) ^a	90 (80, 95)	90 (80, 95)	-	0.10
Barthel Index change from baseline to 3 months, median (IQR) ^a	15 (5, 35)	15 (5, 30)	-	0.01
Platelet counts and coagulation indicators, median (IQR)				
Platelet counts, 10 ⁹ /L ^a	215.5 (173, 255)	216 (178, 259)	-	0.14
PT, s ^a	11.5 (10.7, 12.5)	11.4 (10.6, 12.4)	-	0.63
APTT, s ^a	28.6 (24.8, 33.1)	28.1 (24.8, 33.1)	-	0.58

XST, Xuesaitong soft capsule; OR, odds ratio; HR, hazard ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; EQ-5D, EuroQoL Group 5-Dimension; PT, prothrombin time; APTT, activated partial thromboplastin time.

^a Data of NIHSS score change from baseline to 3 months were missing in 40 patients; Data of EQ-5D score at 3 months were missing in 40 patients; Data of Barthel Index change from baseline to 3 months were missing in 40 patients; Data of platelet counts, PT, and APTT at 3 months were missing in 252, 287, and 297 patients, respectively. The number of missing data was similar between the two groups.

eTable 4. Efficacy Outcomes at 12 months in the Per-Protocol Cohort

	XST group (n=1081)	Control group (n=1096)	OR/HR (95% CI)	P value
Secondary outcomes				
Recurrent stroke, n (%)	23 (2.1)	30 (2.7)	0.78 (0.45 to 1.34)	0.36
Functional independence at 12 months, n (%) ^a	982 (93.1)	990 (92.3)	1.13 (0.81 to 1.56)	0.47
No or minimal disability, n (%) ^a	918 (87.0)	894 (83.3)	1.34 (1.06 to 1.71)	0.02
Composite cerebrovascular events, n (%)	26 (2.4)	32 (2.9)	0.82 (0.49 to 1.38)	0.46
EQ-5D score, median (IQR) ^a	95 (90, 98)	95 (90, 96)	-	0.15
Barthel Index change from baseline to 12 months, median (IQR) ^a	20 (5, 40)	20 (5, 40)	-	0.21

XST, Xuesaitong soft capsule; OR, odds ratio; HR, hazard ratio; CI, confidence interval; EQ-5D, EuroQoL Group 5-Dimension; IQR, interquartile range.


^a Functional outcome data at 12 months was missing in 49 patients; Data of EQ-5D score at 12 months were missing in 56 patients; Data of Barthel Index change from baseline to 12 months were missing in 54 patients. The number of missing data was similar between the two groups.

eTable 5. Medications and Status at 1 month in the modified Intention-To-Treat Cohort

	XST group (n=1487)	Control group (n=1479)	<i>P</i> value
Antithrombotic agents, n (%)	1434 (96.4)	1432 (96.8)	0.56
Antihypertensive agents, n (%)	637 (42.8)	600 (40.6)	0.21
Antidiabetic agents, n (%)	319 (21.5)	297 (20.1)	0.36
Anticholesteremic agents, n (%)	939 (63.1)	919 (62.1)	0.57
mRS score, median (IQR)	1 (1, 2)	1 (1, 2)	0.87
Functional independence, n (%)	1161 (78.1)	1134 (76.7)	0.36
NIHSS score, median (IQR) ^a	3 (2, 4)	3 (2, 4)	0.76
Rehabilitation therapy, n (%)	99 (6.7)	102 (6.9)	0.80


XST, Xuesaitong soft capsule; mRS, modified Rankin Scale; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale.

^a Data of NIHSS score were missing in 2 patients in XST group.



eFigure 1. Distribution of the modified Rankin Scale at 3 months in the Per-Protocol Cohort

XST, Xuesaitong soft capsule.



eFigure 2. Subgroup Analyses in the Per-Protocol Cohort

XST, Xuesaitong soft capsule; OR, odds ratio; CI, confidence interval; TOAST, Trial of Org 10172 in Acute Stroke Treatment.

eAppendix. Trial Organization

Steering Committee:

Xunming Ji; Ying Gao; Haiqing Song; Chi Zhang; Anxin Wang.

Executive Committee:

Xunming Ji; Ying Gao; Haiqing Song; Longfei Wu; Chi Zhang; Luda Feng; Anxin Wang.

Clinical Centers (Principal Investigator):

Xuanwu Hospital, Capital Medical University: Xunming Ji and Haiqing Song; Dongzhimen Hospital, Beijing University of Chinese Medicine: Ying Gao; First Affiliated Hospital of Anhui University of Science and Technology (First People's Hospital of Huainan): Mei Zhang; Dongfang Hospital, Beijing University of Chinese Medicine: Rongjuan Guo; Parrocket Force General Hospital: Lei Wang; The Second People's Hospital of Shenzhen: Lijie Ren; Zhuhai People's Hospital: Guangsen Cheng; Guizhou Provincial People's Hospital: Xiao Hu; Hengshui People's Hospital: Yan Wei; The First Hospital of Hebei Medical University: Yanyong Wang; The Third Hospital of Shijiazhuang: Zhigang Yao; The First Affiliated Hospital of Zhengzhou University: Yuming Xu; Henan Provincial People's Hospital: Liangfu Zhu; First People's Hospital of Zhengzhou City: Xiaoman Zhang; The Second Affiliated Hospital of Harbin Medical University: Lihua Wang; The Third People's Hospital of Hubei Province: Xiaoxiang Peng; The First People's Hospital of Wuhan: Guohua Chen; Xiangya Hospital, Central South University: Yunhai Liu; The Fourth Hospital of Changsha: Huiyun Yu; Xiangtan Central Hospital: Guangxiong Yuan; Nanjing First Hospital: Hongdong Zhao; The First Affiliated Hospital of Soochow University: Qi Fang; The Affiliated Hospital of Xuzhou Medical University: Deqin Geng; Jiangxi Provincial People's Hospital: Fan Hu; Liaocheng People's Hospital: Xiaofeng Yang; Shandong Provincial Hospital Affiliated to Shandong First Medical University: Chuanqiang Qu; Weihai Municipal Hospital: Zhenguang Li; Shanxi Provincial People's Hospital: Fengyun Hu; Hancheng Jiaoda Hospital: Meiyong Deng; Shanghai Pudong Hospital, Fudan University Pudong Medical Center: Shuangxing Hou; Tongji Hospital of Tongji University: Geyong Wang; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine: Zhenguo Liu; Changhai Hospital, Naval Medical University: Benqiang Deng; Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine: Mingzhe Wang; West China Hospital, Sichuan University: Li He; Sichuan Provincial People's Hospital: Fuqiang Guo; The First People's Hospital of Yibin: Hao Li; Suining Central Hospital: Ming Yu; The Second Hospital of Tianjin Medical University: Xin Li; Tianjin Hospital of ITCWM-Nankai Hospital: Heng Wang; First Affiliated Hospital of Kunming Medical University: Lianmei Zhong; The Second Affiliated Hospital of Kunming Medical University: Mei Yin; Yan'an Hospital Affiliated to Kunming Medical University: Liping Zhan; Zigong First People's Hospital: Linming Huang; The Third People's Hospital of Mianyang: Bo Liu; Zigong Fourth People's Hospital: Guibin Wen; The People's Hospital of Dujiangyan: Zhong Zhang; Qinghe People's Hospital: Yingzhuo Zang; Anyang District Hospital: Jinxing Qi; The First Affiliated Hospital of Jiamusi University: Yaojia Jiang; Yanbian University Hospital: Meizi Jiang; Ankang Central Hospital: Kaifu Jiang; Zhengzhou Central Hospital: Runqing Wang; Luoyang Central Hospital Affiliated to Zhengzhou University: Congming Ma; Zhoukou Central Hospital: Lei Xia; Affiliated Hospital of Chengde Medical University: Yanjun Gao; Jiang'an County People's Hospital: Chiyu Xiong; Xuzhou First People's Hospital: Qing He; Jiangsu Province Hospital: Qi Niu; Dalian Municipal Central Hospital: Cui Wang; Linfen Central Hospital: Wanying Li; Gongxian People's Hospital, Yibin City: Jiping Long; Chifeng Municipal Hospital: Wenli Li; Hegang People's Hospital: Fugang Zhong; Hongqi Hospital Affiliated to Mudanjiang Medical University: Yindong Yang; Inner Mongolia Autonomous Region People's Hospital: Runxiu Zhu; Xianyang Hospital of Yanan University: Bingju Wang.

Data and Safety Monitoring Board:

Yi Yang; Yun Xu; Xiuhua Guo.

Events Adjudication Committee:

Huisheng Chen; Lan Chu; Tao Chen.

Data Management and Biostatistics:

Anxin Wang; Yingting Zuo; Xiaoli Zhang.

Trial Coordination:

Haiqing Song; Hong Zhang; Luda Feng.